NCT05100862 2026-03-18
MAHOGANY
BeOne Medicines
Phase 3 Recruiting
Clinical Trials
11 trialsNCT05783596 2026-03-16
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT07355699 2026-01-21
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
Beijing Tongren Hospital
Phase 4 Recruiting
NCT05326308 2025-09-23
ARIADNE
iOMEDICO AG
Recruiting
NCT02992522 2025-09-09
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT05653271 2025-08-11
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Acepodia Biotech, Inc.
Phase 1 Recruiting
NCT01995669 2025-06-24
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03432741 2025-05-26
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Phase 1 Terminated
NCT04578600 2025-04-24
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
University of California, Davis
Phase 1 Completed
NCT05169658 2025-04-11
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Completed
NCT03322865 2025-04-04
Obinutuzumab in Marginal Zone Lymphoma
University of Ulm
Phase 2 Active not recruiting